Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

NCT01600716 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT01600716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01600716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Lead sponsor
Allergan
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2012
Completion date
March 27, 2015
Enrollment
144 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, neurogenic bladder, urinary incontinence